The ONCOSCREEN project seeks to develop new methods and technologies for cancer screening and early detection. The core objective of ONCOSCREEN is to enhance citizen awareness, participation, and acceptance of colorectal cancer screening programmes. The ONCOSCREEN Consortium consists of 38 partner organisations representing 15 countries across Europe. The ONCOSCREEN project is funded under the European Union's Horizon Europe research and innovation programme under grant agreement no. 101097036 and is coordinated by EXUS AI Labs.
Views and opinions expressed are of the project owner only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.
Company Details
- Founded
- -
- Address
- Athens, Gr
- Industry
- Research Services
- NAICS
-
Scientific Research and Development ServicesResearch and Development in the Physical, Engineering, and Life SciencesResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Keywords
- Oncology screening, Colorectal cancer, Cancer prevalence and risk, Integrated diagnostics, Cancer Screening, Cancer Research, Research and Innovation action, Mission Cancer, Horizon Europe.
- HQ
- Athens
Oncoscreen Questions
Oncoscreen's LinkedIn profile is https://gr.linkedin.com/company/oncoscreen
Oncoscreen's industry is
Research Services
Oncoscreen's top competitors are
Uab "varutis",
Hospiton.lt,
Textended,
Optipex,
Humadex,
Pancaid,
Cancer Prevention And Early Detection (Screening),
Oncodir,
Kimitisik,
Dioptra Project.
Oncoscreen's categories are Research Services
Oncoscreen's founding year is 2022
